Know Cancer

or
forgot password

Predictive Value of FDG-TEP During Radiotherapy (RT) or Chemo-radiotherapy (CRT) in Patients With Non Small Cell Lung Cancer on the One-year Survival


N/A
18 Years
N/A
Open (Enrolling)
Both
Lung Cancer, NSCLC

Thank you

Trial Information

Predictive Value of FDG-TEP During Radiotherapy (RT) or Chemo-radiotherapy (CRT) in Patients With Non Small Cell Lung Cancer on the One-year Survival


Inclusion Criteria:



- Histologically confirmed non-small cell lung cancer

- Fertile patients must use effective contraception

- WHO performance status <2

- Measurable disease, defined as at least one lesion that can be accurately measured in
at least one dimension (≥ 10 mm with spiral CT scan)

Exclusion Criteria:

- Pregnant or lactating females

- Baseline fludeoxyglucose F 18 (FDG)-positron emission tomography (PET) scan without
any target lesion

- Unable to under PET CT evaluation

- other concurrent investigational agents

- No Planning to undergo curative intent radiotherapy

- familial, social, geographic, or psychological conditions that would preclude study
participation

- Prior malignancy progressive disease

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label

Outcome Measure:

SUV max from FDG PETScan

Outcome Description:

Measure of FDG-TEP uptake variation (SUV max) to assess predictive value of FDG-TEP during radiotherapy

Outcome Time Frame:

Baseline - 5 Weeks after begining of radiotherapy- 3 months after end of radiotherapy- 1 year afterwards

Safety Issue:

No

Principal Investigator

Bernard DUBRAY, phD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Centre Henri Becquerel

Authority:

France: Institutional Ethical Committee

Study ID:

CHB06-02

NCT ID:

NCT01261598

Start Date:

November 2007

Completion Date:

June 2014

Related Keywords:

  • Lung Cancer
  • NSCLC
  • Positron-Emission Tomography
  • PET Scan
  • Non-Small-Cell Lung Carcinoma
  • Radiation Oncology
  • SUV
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms

Name

Location